Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Evogene ( (EVGN) ) has issued an update.
On February 25, 2026, Evogene released a CEO letter to shareholders outlining a strategic transformation undertaken in 2025 to sharpen its focus and capital allocation. The company consolidated technology development around its ChemPass AI™ platform and narrowed operations to two core markets, human health and agriculture, restructuring the organization and divesting non-core assets to become more agile and capital-efficient.
The letter highlighted ChemPass AI™’s ability to generate original small molecules from a 38-billion-compound universe while meeting complex multi-parameter requirements, underpinning collaborations such as an ongoing second project with Google Cloud. Evogene reported progress in multiple partnered drug discovery programs in human health and continued growth in agricultural collaborations through its AgPlenus subsidiary with partners including Bayer and Corteva, while retaining selective exposure to remaining assets like Casterra.
The most recent analyst rating on (EVGN) stock is a Hold with a $0.98 price target. To see the full list of analyst forecasts on Evogene stock, see the EVGN Stock Forecast page.
Spark’s Take on EVGN Stock
According to Spark, TipRanks’ AI Analyst, EVGN is a Neutral.
Evogene’s overall stock score is primarily impacted by its weak financial performance and poor valuation metrics. While the earnings call provided some positive insights into cost management and strategic initiatives, the company’s financial instability and bearish technical indicators weigh heavily on the score.
To see Spark’s full report on EVGN stock, click here.
More about Evogene
Evogene Ltd. is a computational chemistry company listed on Nasdaq and TASE, specializing in generative AI design of small molecules for the pharmaceutical and agricultural industries. Its core technology, ChemPass AI™, is a proprietary engine that designs novel, highly potent small molecules optimized across multiple parameters to improve development success rates while reducing time and costs.
Leveraging this platform, Evogene targets human health applications, particularly small-molecule therapeutics, and agricultural solutions such as novel ag-chemicals. The company advances its pipeline through a mix of strategic partnerships and internal programs, working with major industry players and academic institutions to translate its AI-driven innovation into commercial products.
Average Trading Volume: 443,024
Technical Sentiment Signal: Sell
Current Market Cap: $7.31M
Learn more about EVGN stock on TipRanks’ Stock Analysis page.